{"filing":{"accession_number":"0001104659-26-097092","cik":"0001175151","ticker":"CTSO","company_name":"Cytosorbents Corp","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-13","primary_document":"tm2623298d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926097092/tm2623298d1_8k.htm"},"events":[{"id":27880,"run_id":25456,"accession_number":"0001104659-26-097092","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the results of CytoSorbents' 2026 Annual Meeting of Stockholders held on August 13, 2026, including voting outcomes on five proposals: election of five directors, advisory approval of named executive officer compensation, ratification of the independent auditor (WithumSmith+Brown, PC), approval of a reverse stock split (1-for-5 to 1-for-20 ratio), and approval of an adjournment provision. All proposals passed. The disclosure includes detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.","company_name":"Cytosorbents Corp","ticker":"CTSO","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29587,"accession_number":"0001104659-26-097092","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of CytoSorbents' 2026 Annual Meeting of Stockholders held on August 13, 2026, including voting outcomes on five proposals: election of five directors, advisory approval of named executive officer compensation, ratification of the independent auditor (WithumSmith+Brown, PC), approval of a reverse stock split (1-for-5 to 1-for-20 ratio), and approval of an adjournment provision. All proposals passed. The disclosure includes detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:17:54.767337+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29587,"accession_number":"0001104659-26-097092","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of CytoSorbents' 2026 Annual Meeting of Stockholders held on August 13, 2026, including voting outcomes on five proposals: election of five directors, advisory approval of named executive officer compensation, ratification of the independent auditor (WithumSmith+Brown, PC), approval of a reverse stock split (1-for-5 to 1-for-20 ratio), and approval of an adjournment provision. All proposals passed. The disclosure includes detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:17:54.767337+00:00","company_name":"Cytosorbents Corp","ticker":"CTSO","filing_date":"2026-08-14"}]}